$4.01
0.74% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US1628281073
Symbol
CKPT
Sector
Industry

Checkpoint Therapeutics, Inc. Stock price

$4.01
+1.38 52.47% 1M
+1.79 80.63% 6M
+0.81 25.31% YTD
+2.14 114.44% 1Y
-13.69 77.34% 3Y
-8.29 67.40% 5Y
-45.99 91.98% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.03 0.74%
ISIN
US1628281073
Symbol
CKPT
Sector
Industry

Key metrics

Market capitalization $335.89m
Enterprise Value $329.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8,232.25
P/S ratio (TTM) P/S ratio 8,397.25
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -60.19%
Revenue (TTM) Revenue $40.00k
EBIT (operating result TTM) EBIT $-56.17m
Free Cash Flow (TTM) Free Cash Flow $-31.10m
Cash position $6.60m
EPS (TTM) EPS $-1.27
P/E forward negative
P/S forward 8.17
EV/Sales forward 8.01
Short interest 9.86%
Show more

Is Checkpoint Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Checkpoint Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Checkpoint Therapeutics, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Checkpoint Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.04 0.04
60% 60%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
131% 131%
50,150%
- Research and Development Expense 36 36
17% 17%
90,375%
-56 -56
8% 8%
-140,425%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -56 -56
8% 8%
-140,435%
Net Profit -56 -56
8% 8%
-140,600%

In millions USD.

Don't miss a Thing! We will send you all news about Checkpoint Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Checkpoint Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Neutral
Business Wire
22 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contin...
Neutral
GlobeNewsWire
23 days ago
PHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced buyout of Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT) shareholders.
More Checkpoint Therapeutics, Inc. News

Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.

Head office United States
CEO James Oliviero
Employees 24
Founded 2014
Website www.checkpointtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today